BEST study: one-year descriptive follow-up of bevacizumab treatment in hereditary haemorrhagic telangiectasia post-BABH interventional study.

ABSTRACT:

Background

Hereditary haemorrhagic telangiectasia (HHT) is a genetic vascular disorder characterised by telangiectases, which cause nasal and gastrointestinal (GI) bleeding, and visceral arteriovenous malformations. Since 2012 bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, has been a promising treatment for HHT-related bleeding and was evaluated in the phase II BABH study.

Objective

To follow and describe evolution and treatments of patients with HHT post-BABH study.

Design

This study is a 1-year, multi-centre descriptive study.

Methods

We collected clinical (nose and GI bleeding, red blood cell transfusions) and biological (haemoglobin and ferritin levels) data and treatment information.

Results

Of 22 patients included

SUBMITTER: Dupuis-Girod S 

PROVIDER: S-EPMC12033602 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature